The Fritillaria alkaloid peiminine acts as a chemosensitizer to potentiate oxaliplatin efficacy against gastric cancer
Pathology - Research and Practice · 2025
DOI: 10.1016/j.prp.2025.156208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2025. Verfasst von Jing Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Life Science, Northwest University, 229 Taibai North Road, Xi'an, Shaanxi, China; State Key Laboratory of Holistic Integrative Management …. Hauptthemen laut MEDLINE: Stomach Neoplasms, Oxaliplatin, Fritillaria, Cevanes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Natural Science Foundation of Xinjiang Uygur Autonomous Region, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Fritillaria walujewii Regel (Xinjiang Bei-Mu), an authentic ("Dao-di") medicinal herb documented in Chinese pharmacopoeias, is traditionally used to treat respiratory disorders. Its principal steroidal alkaloid, peiminine (PMI), demonstrates significant anticancer activity. Oxaliplatin (Oxa), a first-line chemotherapeutic cornerstone for gastric cancer (GC), is limited clinically by intrinsic chemoresistance. Natural product-derived monomers represent a promising strategy for developing chemosensitizers to overcome such resistance. However, the potential of PMI to counteract Oxa chemoresistance and its underlying mechanisms remain unexplored, warranting comprehensive investigation. To determine the chemosensitizing effects of PMI in combination with Oxa for GC treatment, specifically evaluating its capacity to reverse chemoresistance and enhance therapeutic efficacy. MATERIALS AND METHODS: The effects of PMI combined with Oxa versus Oxa monotherapy on GC cells (HGC27, BGC823, MKN45) were assessed using CCK-8, colony formation, and flow cytometry apoptosis assays to evaluate cell proliferation and apoptosis. Subsequently, qPCR-based apoptosis pathway array and transcriptome sequencing (RNA-seq) were used to differentially expressed apoptosis-related genes and to uncover key signaling pathways mediating PMI-induced Oxa sensitization. The protein expression level of Bcl-2, Bax, PARP, cytochrome c (CYCS), Caspase-3/9, RAS and AKT was determined by Western blot. Finally, the efficacy of PMI+Oxa combination therapy was validated in vivo using both cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models. RESULTS: PMI (50 μM) synergized with Oxa (2.5 μM), significantly enhancing apoptosis and suppressing proliferation in GC cells. Mechanistically, the combination activated the mitochondrial apoptosis pathway by upregulating Bax and inducing the release of CYCS and the cleavage of caspase-9, caspase-3, and PARP. Concurrently, it suppressed the RAS/PI3K/AKT survival pathway by inhibiting Ras-GTP and phospho-AKT. In CDX models, PMI (2 mg/kg) + Oxa achieved a tumor growth inhibition (TGI) rate of > 80.8 %, compared to 20.4 % for Oxa alone. Strikingly, in PDX models which preserve clinical tumor heterogeneity-the combination induced a TGI of > 70 % without exacerbating systemic toxicity. CONCLUSIONS: PMI is a novel dual-targeting chemosensitizer that overcomes Oxa resistance by simultaneously activating intrinsic apoptosis and inhibiting pro-survival signaling. Its demonstrated efficacy in clinically relevant PDX models highlights its significant translational potential for platinum-resistant GC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Life Science, Northwest University, 229 Taibai North Road, Xi'an, Shaanxi, China; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for…
- Department of Military and Special Medicine, No. 971 Hospital of the PLA Navy, Qingdao, Shandong, China.
- Department of Critical Care Medicine, the 940th Hospital of Joint Logistics Support Force of PLA, Lanzhou, Gansu, China.
- Faculty of Life Science, Northwest University, 229 Taibai North Road, Xi'an, Shaanxi, China.
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University…
- Key Laboratory of Xinjiang Uighur Medicine, Xinjiang Institute of Materia Medica, Urumqi, Xinjiang, China.
Förderung
- Natural Science Foundation of Xinjiang Uygur Autonomous Region
- National Natural Science Foundation of China
Zitieren
APA
Zhang, J., Zhang, L., Wang, C., Liu, H., Dai, S., Sun, L., Gao, X., Zhang, L., Wang, Y., Yuan, Q., Zhang, Z., Zhao, S., Fan, W., Du, X., Gu, Z., & Nie, Y. (2025). The Fritillaria alkaloid peiminine acts as a chemosensitizer to potentiate oxaliplatin efficacy against gastric cancer. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2025.156208
Vancouver
Zhang J, Zhang L, Wang C, Liu H, Dai S, Sun L, et al. The Fritillaria alkaloid peiminine acts as a chemosensitizer to potentiate oxaliplatin efficacy against gastric cancer. Pathology - Research and Practice. 2025. doi:10.1016/j.prp.2025.156208
BibTeX
@article{Zhang2025,
author = {Zhang, Jing and Zhang, Lu and Wang, Chenchen and Liu, Hui and Dai, Sitian and Sun, Lijuan and Gao, Xianchun and Zhang, Liang and Wang, Yunfei and Yuan, Qiangqiang and Zhang, Zhongyang and Zhao, Sheng and Fan, Wenjing and Du, Xinyu and Gu, Zhengyi and Nie, Yongzhan},
title = {The Fritillaria alkaloid peiminine acts as a chemosensitizer to potentiate oxaliplatin efficacy against gastric cancer},
journal = {Pathology - Research and Practice},
year = {2025},
doi = {10.1016/j.prp.2025.156208}
}
EUVIMED